765 related articles for article (PubMed ID: 27501770)
21. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
23. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.
Trkova M; Prochazkova K; Krutilkova V; Sumerauer D; Sedlacek Z
Cancer; 2007 Aug; 110(3):694-702. PubMed ID: 17567834
[TBL] [Abstract][Full Text] [Related]
24. Parent decision-making around the genetic testing of children for germline TP53 mutations.
Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
[TBL] [Abstract][Full Text] [Related]
25. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
26. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
[TBL] [Abstract][Full Text] [Related]
27. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
28. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
29. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
[TBL] [Abstract][Full Text] [Related]
30. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
[TBL] [Abstract][Full Text] [Related]
31. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
[TBL] [Abstract][Full Text] [Related]
32. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.
Fortuno C; Pesaran T; Mester J; Dolinsky J; Yussuf A; McGoldrick K; James PA; Spurdle AB
Cancer Genet; 2020 Oct; 248-249():11-17. PubMed ID: 32966936
[TBL] [Abstract][Full Text] [Related]
33. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
34. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
[TBL] [Abstract][Full Text] [Related]
36. Transmission of a
Cotter JA; Szymanski L; Karimov C; Boghossian L; Margol A; Dhall G; Tamrazi B; Varaprasathan GI; Parham DM; Judkins AR; Biegel JA
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29581140
[TBL] [Abstract][Full Text] [Related]
37. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
38.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
39. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
40. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
